Help reduce screen failures in NASH clinical trials using K18 Biomarkers. Visit us at The Liver Meeting® to learn more.

Event Date: November 9 - 13, 2018

Event Location:

New Biomarkers for Liver and Kidney Toxicity Studies

 

New Biomarkers for Liver and Kidney Toxicity Studies

 

Panels of Biomarkers for

NAFLD, NASH, AH, and DILI Research Featuring K18

 

 

Visit us at Booth 601

Diapharma invites you to stop by booth 601 while attending The Liver Meeting® 2018 in San Francisco, CA, November 9 – 13.

 

Visit Diapharma to discuss K18 assays as prescreening tools and secondary endpoints in NASH clinical trials.

Learn about our panels of mechanistic biomarkers that provide insight into the biological process occurring during liver injury.

  • M30 Apoptosense®
  • M65 EpiDeath®
  • M65® ELISA

Research use only in the U.S. and Canada

New Biomarkers for Liver and Kidney Toxicity Studies

Diapharma Group, Inc., 8948 Beckett Rd., West Chester, OH 45069

ML-00-00392Rev01